Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy
The journal Neuromodulation published full 36-month results from the CORE-VNS study of LivaNova's VNS Therapy in drug-resistant epilepsy, showing a 76% median reduction in seizure frequency with durable, increasing benefit over time. At 36 months, 16% of participants achieved complete seizure freedom, 64% achieved at least a 50% seizure reduction, and seizure-related hospitalizations fell 73%, with no new safety concerns identified.
Key figures
- Drug Name
- VNS Therapy
- Phase Of Trial
- observational CORE-VNS study (36-month outcomes)
- Study sites
- 61 sites in 16 countries
- Retention rate
- 80%
- Study participants
- 531
- Seizure freedom rate
- 16%
- Median seizure reduction
- 76%
- Hospitalization reduction
- 73%
- Participants responders 50pct
- 64%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.